Rifampin, a CYP3A4 inducer, noticeably lowered the publicity to and the pharmacodynamic results of zolpidem. Utilization of Rifampin in combination with zolpidem could decrease the efficacy of zolpidem. Coadministration of zolpidem with other CNS depressants increases the potential risk of CNS me